FDA
-
-
-
-
-
-
-
Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices An
-
-
-
-
-
-
-
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Celularity Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Celularity (CELU) Granted FDA Fast Track Designation for NK Cell Therapy CYNK-001 in Development for the Treatment of AML
-
-
-
-
-
-
251,890 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All